Grothey A - Search Results

1

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Grothey A, et al. Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177514 Clinical Trial.

2

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Grothey A, et al. J Clin Oncol. 2004 Apr 1;22(7):1209-14. doi: 10.1200/JCO.2004.11.037. J Clin Oncol. 2004. PMID: 15051767

3

Developments in combination chemotherapy for colorectal cancer.

Goetz MP, Grothey A. Goetz MP, et al. Among authors: grothey a. Expert Rev Anticancer Ther. 2004 Aug;4(4):627-37. doi: 10.1586/14737140.4.4.627. Expert Rev Anticancer Ther. 2004. PMID: 15270666 Review.

4

Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).

Marsé H, Van Cutsem E, Grothey A, Valverde S. Marsé H, et al. Among authors: grothey a. Eur J Oncol Nurs. 2004;8 Suppl 1:S16-30. doi: 10.1016/j.ejon.2004.06.006. Eur J Oncol Nurs. 2004. PMID: 15341879 Review.

5

A review of oxaliplatin and its clinical use in colorectal cancer.

Grothey A, Goldberg RM. Grothey A, et al. Expert Opin Pharmacother. 2004 Oct;5(10):2159-70. doi: 10.1517/14656566.5.10.2159. Expert Opin Pharmacother. 2004. PMID: 15461551 Review.

6

FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.

Grothey A, Sargent DJ. Grothey A, et al. J Clin Oncol. 2005 May 20;23(15):3311-3. doi: 10.1200/JCO.2005.11.691. J Clin Oncol. 2005. PMID: 15908645 No abstract available.

7

Clinical trial designs for prospective validation of biomarkers.

Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ. Mandrekar SJ, et al. Among authors: grothey a. Am J Pharmacogenomics. 2005;5(5):317-25. doi: 10.2165/00129785-200505050-00004. Am J Pharmacogenomics. 2005. PMID: 16196501

8

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Sargent DJ, et al. Among authors: grothey a. J Clin Oncol. 2005 Dec 1;23(34):8664-70. doi: 10.1200/JCO.2005.01.6071. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260700

9

Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.

Kim GP, Grothey A. Kim GP, et al. Among authors: grothey a. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S89-97. doi: 10.3816/ccc.2005.s.012. Clin Colorectal Cancer. 2005. PMID: 16336754 Review.

10

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.

Grothey A, Sargent D. Grothey A, et al. J Clin Oncol. 2005 Dec 20;23(36):9441-2. doi: 10.1200/JCO.2005.04.4792. J Clin Oncol. 2005. PMID: 16361649 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

378 results

Search Page